5-Bromo-1,3,5-trimethyl-pyrimidine-2,4,6-trione | 15937-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Bromo-1,3,5-trimethyl-pyrimidine-2,4,6-trione
• 英文别名: 5-Bromo-1,3,5-trimethyl-1,3-diazinane-2,4,6-trione
• CAS: 15937-68-5
• 化学式: C₇H₉BrN₂O₃
• 分子量: 249.064
• InChiKey: ZPKBROSGVIZFIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  57.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Bromo-1,3,5-trimethyl-pyrimidine-2,4,6-trione 在 氨 作用下， 生成 5-amino-1,3,5-trimethyl-barbituric acid
  参考文献：
  名称：

  Goldhahn, Pharmazie, 1957, vol. 12, p. 549,550

  摘要：

  DOI：

文献信息

• US2078323
  申请人：——

  公开号：——

  公开（公告）日：——
• DE602217
  申请人：——

  公开号：——

  公开（公告）日：——
• US20140275134A1
  申请人：——

  公开号：US20140275134A1

  公开（公告）日：2014-09-18
• N-SUBSTITUTED HYDROXYLAMINE DERIVATIVES WITH CARBON-BASED LEAVING GROUPS
  申请人：The Johns Hopkins University

  公开号：US20160115148A1

  公开（公告）日：2016-04-28

  The disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.
• MELDRUM'S ACID, BARBITURIC ACID AND PYRAZOLONE DERIVATIVES SUBSTITUTED WITH HYDROXYLAMINE AS HNO DONORS
  申请人：The Johns Hopkins University

  公开号：US20170050947A1

  公开（公告）日：2017-02-23

  The disclosed subject matter provides certain N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.